Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Sodium butyrate / tributyrin

Sodium Butyrate / Tributyrin · also known as Butyrate, Tributyrin, Postbiotic Butyrate

Butyrate is an important energy source for colonic epithelial cells. In animal models it can regulate tight junction proteins, and in experimental studies it can also inhibit HDAC and promote the differentiation of some regulatory T cells. It is not yet clear whether standard oral products reach effective concentrations in the human colon.

Typical dose: Enteric-coated microencapsulated sodium butyrate is commonly used at 500–1500 mg/day, and tributyrin at 500–1000 mg/day. The labeled weight of different products does not correspond to the same amount of butyrate, so treat these figures as a rough guide and go by the butyrate content stated on the product label.
Absorption and forms: Regular sodium butyrate has a pungent smell and is absorbed in the upper digestive tract, so how much reaches the colon is unclear. Enteric-coated microcapsules and tributyrin are common improved forms. Tributyrin can be broken down by gastric and pancreatic lipase, so it cannot be guaranteed to reach the distal colon, and the release site of each product needs to be checked separately. Labeled weights for different salts, encapsulated forms and glycerides should not be treated as equal amounts of butyrate.

Clinical uses and human evidence

Irritable bowel syndrome

BeneficialGrade B · Moderate evidence
Studies (2)
  1. Banasiewicz 2013 · Colorectal Dis · RCT · n=66 — Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome
  2. Panufnik 2026 · Sci Rep · RCT · n=52 — Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial

Diarrhea (including antibiotic-associated diarrhea)

BeneficialGrade C · Preliminary evidence
Studies (1)
  1. Panufnik 2026 · Sci Rep · RCT · n=52 — Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial

Blood sugar and insulin resistance

Mixed resultsGrade C · Preliminary evidence
Studies (2)
  1. Panufnik 2026 · Sci Rep · RCT · n=52 — Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial
  2. Testa 2026 · Clin Nutr · RCT · n=46 — Targeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: A proof-of-concept randomized controlled trial

Body weight and body fat

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Testa 2026 · Clin Nutr · RCT · n=46 — Targeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: A proof-of-concept randomized controlled trial

Mechanisms of action

Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair

★★★☆☆Mechanism evidence: grade CSecondary target

Butyrate is an important fuel for colonic epithelial cells. In animal models, including mice with scald burns, it can reduce the rise in intestinal permeability and the tight junction protein abnormalities. How much of a standard oral product reaches the human colon, and how ZO-1 and Occludin respond in humans, has not been established.

References (2)
  1. Liang et al. 2020 · Study in mice with scald burns: sodium butyrate reduced increased intestinal permeability and abnormal tight junction proteins
  2. Tabat et al. 2020 · Ex vivo human colon tissue experiment: butyrate effects varied with experimental conditions and cannot be equated with the results of oral treatment

Epigenetic inhibition of histone deacetylases (HDACs)

★★★☆☆Mechanism evidence: grade CPrimary target

In some experimental models, butyrate can inhibit HDAC and promote the differentiation of some regulatory T cells. The evidence for HDAC inhibition and Foxp3-related acetylation comes from animal and in-vitro studies. Whether standard oral products reach effective concentrations in target human tissues is still uncertain.

References (2)
  1. Furusawa et al. 2013 · Mouse and cell experiments: butyrate promoted the differentiation of colonic regulatory T cells and affected histone acetylation at the Foxp3 locus
  2. Edelman et al. 2003 · Human pharmacokinetic study: examined butyrate exposure from tributyrin at doses far higher than typical supplement doses

Colonic short-chain fatty acid (SCFA/butyrate) fermentation substrate and receptor activation

★★★☆☆Mechanism evidence: grade CPrimary target

Exogenous butyrate can serve as a fuel for the epithelium. Animal studies suggest its protective effect on the intestinal mucosa is linked to GPR109A. There is no direct evidence that standard oral products activate GPR41 and GPR43 in the human colon, and the effect also depends on the product.

References (2)
  1. Gong et al. 2021 · Mouse experiment: butyrate-related protection of the intestinal mucosa involves GPR109A
  2. Overall assessment · Human evidence: no reliable human trial directly shows that standard oral butyrate products activate GPR41 and GPR43 in the colon

Safety and drug interactions

During a severe irritable bowel syndrome (IBS) flare, a few people need to start with a small dose and increase it gradually to build tolerance.
Open in the interactive app ›